Le Lézard
Classified in: Health
Subjects: SVY, TDS

Stevia: Understanding the Sweetener's Role in the Fight against Obesity and Diabetes


ATLANTA, Oct. 23, 2018 /PRNewswire/ -- As registered dietitians from around the world met in Washington, DC this week for the Academy of Nutrition and Dietetics Food and Nutrition Conference Expo (FNCE) to discuss best practices in health and nutrition, the issues of obesity and diabetes were certainly on the agenda. Dr. Keith Ayoob, Associate Clinical Professor Emeritus at the Albert Einstein College of Medicine in New York, has spoken over the past year about his research on these all-too-common health epidemics.

Dr. Keith Ayoob, Associate Clinical Professor Emeritus at the Albert Einstein College of Medicine in New York, spoke about the sweetener stevia at the International Union of Nutritional Sciences (IUNS) International Congress of Nutrition (ICN), held in Buenos Aires, Argentina October 15-20, 2017.

"Obesity is a gateway disease for diabetes as well as chronic conditions including metabolic syndrome, hypertension and cardiovascular risk," said Ayoob. "It's a problem we are facing every day in this country." In response to a 2016 survey conducted by the Harris Poll on behalf of the Calorie Control Council of more than 2,000 American adults, twenty percent said they had been diagnosed with diabetes or prediabetes by a medical professional.

Obesity and diabetes rates are estimated to increase in the future. In North America, the International Diabetes Foundation predicts that 60.5 million people will have diabetes by 2040, compared with 44.3 million in 2015.

The World Health Organization (WHO) recommends a decrease in added sugars to less than 10% of total calories. "Without changes, such as replacing sugar with low and no calorie sweeteners, such as stevia, this level of reduction will be extremely difficult for most people to achieve in the present environment," said Ayoob.

Ayoob took a look at the scientific evidence of stevia in this role, from evidence-based systematic reviews and meta analyses, and found positive impact on insulin signaling and release from in-vitro studies, improved plasma glucose levels in animal studies and reduced postprandial glucose in human studies with persons with diabetes.

In one 16-week study, 122 diabetic adults were given 1000mg of Reb A stevia per day. The study found there to be no negative effects on glycemic load, HbA1C, fasting glucose, or serum insulin.

For a copy of the complete presentation, click here. For more information about stevia, contact the International Stevia Council or the Calorie Control Council.

SOURCE Calorie Control Council


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: